Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enfusion Inc Cl A (NY: ENFN )

9.050 +0.140 (+1.57%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 284,864
Open 8.980
Bid (Size) 8.800 (1)
Ask (Size) 9.290 (1)
Prev. Close 8.910
Today's Range 8.955 - 9.375
52wk Range 7.520 - 10.45
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Enfusion Announces Key Leadership Team Additions to Drive Client Success and Fuel Innovation
From Enfusion, Inc.
Via Business Wire
Enfusion Announces Date of Third Quarter 2024 Results
From Enfusion, Inc.
Via Business Wire

Performance

YTD
-3.42%
-3.42%
1 Month
+1.57%
+1.57%
3 Month
+4.62%
+4.62%
6 Month
-7.46%
-7.46%
1 Year
+5.23%
+5.23%

More News

Read More
ENFN Investors Have Opportunity to Join Enfusion, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
A Glimpse Into The Expert Outlook On Enfusion Through 4 Analysts
Via Benzinga
Earnings Outlook For Enfusion
Via Benzinga
Enfusion, Inc. (ENFN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Enfusion, Inc. (ENFN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ENFN Investors Have Opportunity to Join Enfusion, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
ENFN Stock Earnings: Enfusion Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Enfusion Announces Second Quarter 2024 Results
From Enfusion, Inc.
Via Business Wire
Enfusion Introduces the Next Phase of Portfolio Workbench, Empowering Asset Managers with Increased Efficiency and Flexibility
From Enfusion, Inc.
Via Business Wire
Enfusion Announces Date of Second Quarter 2024 Results
From Enfusion, Inc.
Via Business Wire
Enfusion To Present at Upcoming Investor Events
From Enfusion, Inc.
Via Business Wire
ENFN Stock Earnings: Enfusion Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Enfusion Announces First Quarter 2024 Results
From Enfusion, Inc.
Via Business Wire
Enfusion Announces Date of First Quarter 2024 Results
From Enfusion, Inc.
Via Business Wire
The 3 Most Undervalued Under-$10 Stocks to Buy in April 2024
Via InvestorPlace
Kayne Anderson Strengthens Investment Operations After Successful Platform Migration to Enfusion
From Enfusion
Via Business Wire
Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024
Via InvestorPlace
12 Information Technology Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Enfusion Announces Fourth Quarter 2023 Results and Full Year 2023 Results
From Enfusion, Inc.
Via Business Wire
Earnings Scheduled For March 12, 2024
Via Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, March 2
Via Talk Markets
Enfusion Stock To Remain Range-Bound In 2024 Amid Stable Hedge Fund Market: Goldman Sachs Analyst Downgrades Stock
Via Benzinga
Enfusion Announces Date of Fourth Quarter and Full Year 2023 Results
From Enfusion, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.